These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1095 related articles for article (PubMed ID: 24643604)
1. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. Hayes JH; Barry MJ JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604 [TBL] [Abstract][Full Text] [Related]
2. Screening for prostate cancer. Ilic D; Neuberger MM; Djulbegovic M; Dahm P Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794 [TBL] [Abstract][Full Text] [Related]
3. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018 [TBL] [Abstract][Full Text] [Related]
4. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017 [TBL] [Abstract][Full Text] [Related]
5. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis. Pron G Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236 [TBL] [Abstract][Full Text] [Related]
6. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. de Koning HJ; Gulati R; Moss SM; Hugosson J; Pinsky PF; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; de Carvalho TM; Feuer EJ; Tsodikov A; Mariotto AB; Heijnsdijk EAM; Etzioni R Cancer; 2018 Mar; 124(6):1197-1206. PubMed ID: 29211316 [TBL] [Abstract][Full Text] [Related]
7. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. Ilic D; Djulbegovic M; Jung JH; Hwang EC; Zhou Q; Cleves A; Agoritsas T; Dahm P BMJ; 2018 Sep; 362():k3519. PubMed ID: 30185521 [TBL] [Abstract][Full Text] [Related]
8. Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC). Villers A; Bessaoud F; Trétarre B; Grosclaude P; Malavaud B; Rebillard X; Iborra F; Daubisse L; Malavaud S; Roobol M; Heijnsdijk EA; de Koning HJ; Hugosson J; Rischmann P; Soulié M Prog Urol; 2020 Apr; 30(5):252-260. PubMed ID: 32197936 [TBL] [Abstract][Full Text] [Related]
9. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. Martin RM; Donovan JL; Turner EL; Metcalfe C; Young GJ; Walsh EI; Lane JA; Noble S; Oliver SE; Evans S; Sterne JAC; Holding P; Ben-Shlomo Y; Brindle P; Williams NJ; Hill EM; Ng SY; Toole J; Tazewell MK; Hughes LJ; Davies CF; Thorn JC; Down E; Davey Smith G; Neal DE; Hamdy FC; JAMA; 2018 Mar; 319(9):883-895. PubMed ID: 29509864 [TBL] [Abstract][Full Text] [Related]
10. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Hugosson J; Godtman RA; Carlsson SV; Aus G; Grenabo Bergdahl A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H Scand J Urol; 2018 Feb; 52(1):27-37. PubMed ID: 29254399 [TBL] [Abstract][Full Text] [Related]
11. Screening for prostate cancer: an updated Cochrane systematic review. Ilic D; O'Connor D; Green S; Wilt TJ BJU Int; 2011 Mar; 107(6):882-91. PubMed ID: 21392207 [TBL] [Abstract][Full Text] [Related]
12. Screening for prostate cancer: the current evidence and guidelines controversy. Gomella LG; Liu XS; Trabulsi EJ; Kelly WK; Myers R; Showalter T; Dicker A; Wender R Can J Urol; 2011 Oct; 18(5):5875-83. PubMed ID: 22018148 [TBL] [Abstract][Full Text] [Related]
13. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault]. Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380 [TBL] [Abstract][Full Text] [Related]
14. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. de Koning HJ; Auvinen A; Berenguer Sanchez A; Calais da Silva F; Ciatto S; Denis L; Gohagan JK; Hakama M; Hugosson J; Kranse R; Nelen V; Prorok PC; Schröder FH; ; Int J Cancer; 2002 Jan; 97(2):237-44. PubMed ID: 11774270 [TBL] [Abstract][Full Text] [Related]
15. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*. Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563 [TBL] [Abstract][Full Text] [Related]
16. The current state of prostate-specific antigen testing. Lewis R; Hornberger B JAAPA; 2016 Sep; 29(9):51-3. PubMed ID: 27575906 [TBL] [Abstract][Full Text] [Related]
17. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Lin K; Lipsitz R; Miller T; Janakiraman S; Ann Intern Med; 2008 Aug; 149(3):192-9. PubMed ID: 18678846 [TBL] [Abstract][Full Text] [Related]
18. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Schröder FH Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157 [TBL] [Abstract][Full Text] [Related]